Home › Employers › Priovant Therapeutics, Inc.
Priovant Therapeutics, Inc.: H-1B salaries and sponsorship
Priovant Therapeutics, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $180,000.
Does Priovant Therapeutics, Inc. sponsor H-1B visas?
Priovant Therapeutics, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Jun 2, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Associate, Clinical Operations | 1 | $103,501 |
| Commercial Program Manager | 1 | $180,000 |
| Senior Director, Physician Engagement | 1 | $280,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2025 | 1 | $103,501 |
| FY2026 | 2 | $230,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Senior Director, Physician Engagement | $280,000 Level III | Vista, CA | Jun 2, 2026 | Jun 15, 2026 | Certified |
| Commercial Program Manager | $180,000–$200,000 Level II | San Francisco, CA | Dec 23, 2025 | Jan 5, 2026 | Certified |
| Associate, Clinical Operations | $103,501–$150,000 Level II | Durham, NC | Jun 13, 2025 | Jun 23, 2025 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).